Bioinformatics Links Downregulated MDM2 Protein with Diabetic Kidney Disease Progression

A new bioinformatic framework developed by researchers at University of California (UC) San Diego School of Medicine has identified key proteins significantly altered at the gene-expression level in biopsied tissue from patients with diabetic kidney disease, a result that may reveal new therapeutic targets. In an open-access paper published online on October 20, 2016 in JCI Insight, researchers, led by Kumar Sharma, M.D., Professor of Medicine at UC San Diego School of Medicine, revealed that the protein MDM2 was consistently down-regulated and played a key role in diabetic kidney disease progression. The article is titled “Systems Biology Analysis Reveals Role of MDM2 in Diabetic Nephropathy.” The researchers used the new "MetBridge Generator" bioinformatics framework to identify the relevant enzymes and bridge proteins that link human metabolomics data to the pathophysiology of diabetic kidney disease at a molecular level. "MetBridge Generator allows for efficient, focused analysis of urine metabolomics data from patients with diabetic kidney disease, providing researchers an opportunity to develop new hypotheses based on the possible cellular or physiological role of key proteins," said Dr. Sharma, senior author and Director of the Institute for Metabolomic Medicine and the Center for Renal Translational Medicine at UC San Diego School of Medicine. "The framework may also be used in the interpretation of other metabolomic signatures from a variety of diseases. For example, MDM2 is also involved in regulating tumor protein p53, which is a target for cancer treatments." In a previous study, the authors identified 13 metabolites that were found to be altered in patients with diabetic kidney disease.
Login Or Register To Read Full Story